Eyenovia, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Eyenovia, Inc. | EYEN - NASDAQ |
$10.00-$12.00 | $10.00 | $10.00 | 2.73 million | 1/25/2018 |
| Ladenburg Thalmann, Roth Capital Partners | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2017-12-19 Terms Added 2018-01-09 Final Prospectus 2018-01-25 | ||||||
Eyenovia, Inc. Quote & Chart - Click for current quote - EYEN
IPO Boutique aggregates information on public companies and private companies, such as "EYEN" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Eyenovia, Inc. (adapted from Eyenovia, Inc. prospectus):
They are a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing their patented piezo-print technology to deliver micro-doses of active pharmaceutical ingredients, or micro-therapeutics, topically to the eye.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing their patented piezo-print technology to deliver micro-doses of active pharmaceutical ingredients, or micro-therapeutics, topically to the eye.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "EYEN" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.